Pharmacogenomics: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Robert Badgett |
||
| Line 9: | Line 9: | ||
* The SLCO1B1 Variants and statin-induced myopathy<ref name="pmid18650507"> The SEARCH Collaborative Group. (2008) [http://content.nejm.org/cgi/content/full/NEJMoa0801936 SLCO1B1 Variants and Statin-Induced Myopathy]. New Eng J Med. PMID 18650507</ref> | * The SLCO1B1 Variants and statin-induced myopathy<ref name="pmid18650507"> The SEARCH Collaborative Group. (2008) [http://content.nejm.org/cgi/content/full/NEJMoa0801936 SLCO1B1 Variants and Statin-Induced Myopathy]. New Eng J Med. PMID 18650507</ref> | ||
* [[Toxic epidermal necrolysis]] (TEN) and [[Stevens-Johnson syndrome]] (SJS) patients with [[HLA]]-B*1502 allele who take [[carbamazepine]]<ref>Anonymous. [http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels]. U.S. Food and Drug Administration</ref>. | * [[Toxic epidermal necrolysis]] (TEN) and [[Stevens-Johnson syndrome]] (SJS) patients with [[HLA]]-B*1502 allele who take [[carbamazepine]]<ref>Anonymous. [http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels]. U.S. Food and Drug Administration</ref>. | ||
===Genetic screening=== | |||
[[Mass screening|Screening]] for [[HLA Antigens|HLA]]-B*5701 may reduce the incidence of [[hypersensitivy]] reactions to [[abacavir]] according to a [[randomized controlled trial]].<ref name="pmid18256392">{{cite journal |author=Mallal S, Phillips E, Carosi G, ''et al'' |title=HLA-B*5701 screening for hypersensitivity to abacavir |journal=N. Engl. J. Med. |volume=358 |issue=6 |pages=568–79 |year=2008 |month=February |pmid=18256392 |doi=10.1056/NEJMoa0706135 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=18256392&promo=ONFLNS19 |issn=}}</ref> | |||
==Drug efficacy== | ==Drug efficacy== | ||
Revision as of 11:27, 12 January 2009
Pharmacogenomics, or pharmacogenetics, is the "branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (biotransformation)."[1]
Drug toxicity
Among drugs frequently cited in adverse drug reactions, 60% are metabolized by enzymes with genetic variations in metabolism. 7% to 22% of randomly selected have such variation.[2]
Examples include:
- The SLCO1B1 Variants and statin-induced myopathy[3]
- Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) patients with HLA-B*1502 allele who take carbamazepine[4].
Genetic screening
Screening for HLA-B*5701 may reduce the incidence of hypersensitivy reactions to abacavir according to a randomized controlled trial.[5]
Drug efficacy
Heart failure and hypertension may be an examples were there are racial variations in responses to drugs. Presumably these variations are due to pharmacogenomics.
References
- ↑ Anonymous. Pharmacogenetics. National Library of Medicine. Retrieved on 2008-01-22.
- ↑ Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (2001). "Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review". JAMA 286 (18): 2270–9. PMID 11710893. [e]
- ↑ The SEARCH Collaborative Group. (2008) SLCO1B1 Variants and Statin-Induced Myopathy. New Eng J Med. PMID 18650507
- ↑ Anonymous. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. U.S. Food and Drug Administration
- ↑ Mallal S, Phillips E, Carosi G, et al (February 2008). "HLA-B*5701 screening for hypersensitivity to abacavir". N. Engl. J. Med. 358 (6): 568–79. DOI:10.1056/NEJMoa0706135. PMID 18256392. Research Blogging.
External links
- http://www.pharmgkb.org/ - Pharmacogenetics Research Network and Database (Standford University)
- http://medicine.iupui.edu/flockhart/ - Cytochrome P450 interactions (Indiana University Department of Medicine)
- http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm - Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. U.S. Food and Drug Administration.